Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial
This study is a prospective, double-blind, 1:1:1 randomized controlled study aimed at evaluating the efficacy and safety of Aleeto treatment compared to placebo in improving the NIHSS score at 90 days in patients with moderate to severe acute ischemic stroke. It also aims to explore the neuroprotective effects of Aleeto in moderate to severe acute ischemic stroke and provide data support and evidence for future clinical trials and evidence-based medicine.
The Study of Safety and Preliminary Efficacy of Aleeto in Patients with MultIple System Atrophy
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).
Single-arm, open-label, single-center clinical trial of the safety and preliminary efficacy of ALEETO in the treatment of mild to moderate Alzheimer's disease
